Vobarilizumab

Drug Profile

Vobarilizumab

Alternative Names: ALX 0061; ANTI-IL-6R; Anti-IL-6R Nanobody

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Ablynx
  • Class Antirheumatics; Proteins
  • Mechanism of Action Interleukin 6 receptor antagonists; Interleukin 6 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 28 Nov 2016 Vobarilizumab is available for licensing as of 23 Nov 2016 in Rheumatoid arthritis
  • 09 Aug 2016 Efficacy and adverse events data from a phase IIb trial in Rheumatoid arthritis (Treatment-experienced) released by Ablynx
  • 01 Aug 2016 Ablynx completes a phase IIb trial in Rheumatoid arthritis (Treatment-experienced) in US, Belgium, Bulgaria, Czech Republic, Georgia, Germany, Hungary, Macedonia, Mexico, Moldova, Poland, Romania, Serbia and Spain (NCT02309359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top